Answers are grounded in this paper and cite their sources.
The Mycobacterium abscessus complex (MABC) is an important opportunistic pathogen characterized by multidrug resistance and poor treatment outcomes. However, established resistance determinants do not fully explain phenotypic resistance, and regional genomic data remain limited. This study aimed to compare phenotypic drug susceptibility testing (pDST) with genotypic drug susceptibility testing (gDST) and to characterize the genomic diversity of MABC clinical isolates from Thailand using whole-genome sequencing (WGS). A total of 124 MABC clinical isolates were analyzed using WGS for subspecies identification, multilocus sequence typing (MLST), resistance and virulence gene profiling, mobile genetic element detection, phylogenetic analysis, and investigation of resistance-associated variants. Available pDST results were compared with gDST predictions using categorical agreement and diagnostic performance metrics. The isolates were classified as M. abscessus subsp. abscessus ( n = 65), M. abscessus subsp. massiliense ( n = 53), and M. abscessus subsp. bolletii ( n = 6). Among 117 isolates with available pDST data, resistance was the highest for moxifloxacin (95.73%), followed by clarithromycin at Day 14 (60.68%) and linezolid (54.70%), whereas amikacin resistance was low (5.13%). MLST, genomic characterization, and phylogenetic analyses demonstrated substantial genetic diversity. Established resistance determinants included rrs A1375G for amikacin and erm (41) and rrl variants associated with inducible and acquired clarithromycin resistance. Categorical agreement between gDST and pDST was 95.51% for inducible clarithromycin resistance, 92.86% for acquired clarithromycin resistance, 95.28% for amikacin, and 2.63% for moxifloxacin. Notably, all 64 phenotypically linezolid-resistant isolates lacked recognized linezolid resistance-associated mutations, and 112 of 117 isolates were phenotypically resistant to moxifloxacin despite the absence of recognized QRDR resistance determinants. Several noncanonical variants were identified, but their functional significance remains uncertain. Thai MABC clinical isolates exhibited substantial genomic diversity and marked variation in drug susceptibility. Genotypic prediction showed high categorical agreement for clarithromycin and amikacin but substantial discordance for linezolid and moxifloxacin. These findings demonstrate both the utility and limitations of WGS-based resistance prediction and support the complementary use of phenotypic and genotypic drug susceptibility testing.
No takes yet. Share an insight, caveat, or question.
Prasertsin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: